ORG – Page 255 – Talk Bio

Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors

1 year ago talkbio0Tagged Acquisition (action), biotech, Cytokinetics, Industry, investors, Merger, merger and acquisition, Royalty

Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry

Pharmaceutical Companies Prevail in 340B Case as Appeals Court Upholds Discount Restrictions

1 year ago talkbio0Tagged 340B, Appeals Court, Clinic, discounts, drugmakers, Health care facility, healthcare, Hospitals, Programs - Publication Format

340B program, drugmakers, discounts, Appeals Court, ruling, healthcare, pharmaceuticals, hospitals, clinics.

Palisade Biotechnology’s Novel Ulcerative Colitis Treatment Shows Promising Results in Preclinical Studies

1 year ago talkbio0Tagged Canis familiaris, Drug Development, House mice, Inflammatory Bowel Diseases, Nontoxic, Palisade Biotechnology, preclinical studies, Symptoms aspect, Ulcerative Colitis

Palisade Biotechnology, ulcerative colitis, preclinical studies, nontoxic, mice, dogs, drug development, inflammatory bowel disease, treatment, prevention, symptoms

Evotec Discontinues Gene Therapy Operations, Shuts Down Austria Facility

1 year ago talkbio0Tagged Austria, Biotechnology, business operations, development aspects, Evotec, Facility (object), gene therapy, Reparative closure, research, strategic decision

Evotec, gene therapy, Austria, facility closure, strategic decision, business operations, research and development, biotechnology

Crinetics’s Atumelnant Shows Promising Early Results in Congenital Adrenal Hyperplasia Treatment

1 year ago talkbio0Tagged Adrenal Glands, Androgens, Atumelnant, Clinical Trials, Congenital adrenal hyperplasia, corticotropin, Crinetics, hydrocortisone

Crinetics, Atumelnant, congenital adrenal hyperplasia, early data, treatment, clinical trial, cortisol, androgens, ACTH, adrenal glands.

Revolutionary Oral Treatment for Retinal Disease Shows Promising Results in Phase II Trials

1 year ago talkbio0Tagged Oral treatment, Phase 2 Clinical Trials, Retinal Diseases, Revolutionary, Rezolutes

Retinal disease, oral treatment, Phase II trials, revolutionary, promising results, Rezolutes.

FDA Grants Approval for First Interchangeable Biosimilars to Regeneron’s Eylea

1 year ago talkbio0Tagged Approved, Biosimilars, blockbuster, Diabetic Retinopathy, interchangeable, Macular degeneration, Regeneron, Retinal Vein Occlusion, United States Food and Drug Administration

FDA, biosimilars, interchangeable, Regeneron, Eylea, approval, blockbuster, drug, treatment, eye diseases, macular degeneration, diabetic retinopathy, retinal vein occlusion